



ajanta pharma limited

Ajanta House,
Charkop, Kandivli West,
Mumbai 400 067
India

T +91 22 6606 1000
F +91 22 6606 1200
E info@ajantapharma.com
W www.ajantapharma.com

11th July, 2017

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400001 Scrip Code: BSE - AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: NSE AJANTPHARM EQ
---	---

Re: Compliance with Reg. 27(2) of the Listing Regulations - Report on Corporate Governance

Dear Sir/Madam,

Pursuant to Regulation 27(2) of the Listing Regulation, enclosed please find Quarterly Compliance Report on Corporate Governance for the quarter ended on 30th June, 2017.

Thanking You,

Yours faithfully,


GAURANG SHAH
AVP - Legal &
Company Secretary

Encl.: a/a


1. Name of Listed Entity : Ajanta Pharma Limited

2. Quarter ending : 30th June, 2017

I. Composition of Board of Directors								
Title (Mr./ Ms.)	Name of the Director	PAN ^S & DIN	Category (Chairperson /Executive/ Non-Executive/ independent / Nominee) ^{&}	Date of Appointment in the current term /cessation	Tenure	No of Directorship in listed entities including this listed entity (Refer Regulation 25(1) of Listing Regulations)	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)
Mr.	Mannalal B. Agrawal	AACPA2742D & 00073828	Chairperson	NA	NA	One	Audit - 3 (*) SRC - None	None
Mr.	Purushottam B. Agrawal	AACPA3161C & 00073680	Executive	01.04.2013	NA	One	None	None
Mr.	Madhusudan B. Agrawal	AAHPA8178J & 00073872	Executive	01.04.2015	NA	One	None	None
Mr.	Yogesh M. Agrawal	AACPA2793C & 00073673	Executive	01.04.2013	NA	One	None	None
Mr.	Rajesh M. Agrawal	AACPA2792D & 00302467	Executive	01.05.2013	NA	One	Audit - None SRC - 1	None
Mr.	Chandrakant Khetan	AAHPK5606M & 00234118	Independent	01.04.2014	5 years	Two	Audit - 1 SRC - None	Of 1 Audit Committee
Mr.	Anil Kumar	AABPC8668D & 00208833	Independent	01.04.2014	5 years	One	Audit - None SRC - 1	Of 1 SRC
Mr.	K H Viswanathan	ALJPK1873B & 06563472	Independent	01.04.2014	5 years	One	Audit - 1 SRC - None	None
Mr.	Prabhakar Dalal	ADKPD7258G & 00544948	Independent	01.04.2014	5 years	Three	Audit - 7 (*) SRC - 1	Of 2 Audit Committee (*)
Ms.	Anjana Grewal	AFNPG6211K & 06896404	Independent	01.04.2014	5 years	One	Audit - 2 (*) SRC - 1	None
* Includes membership/chairmanship of unlisted companies also								



II. Composition of Committees			
"SAME AS PREVIOUS QUARTER"			
III. Meeting of Board of Directors			
Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Maximum gap between any two consecutive (in number of days)	
24 th January, 2017 18 th March, 2017	3 rd May, 2017	45 (excluding meeting days)	
IV. Meeting of Committees			
Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (details)	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings in number of days*
Audit Committee: 3 rd May, 2017	Yes, all the Committee members were present	24 th January, 2017 18 th March, 2017	45 (excluding meeting days)
Stakeholders' Relationship Committee: 3 rd May, 2017	Yes, all the Committee members were present	24 th January, 2017	98 (excluding meeting days)
V. Related Party Transactions			
Subject		Compliance status (Yes/No/NA)refer note below	
Whether prior approval of audit committee obtained		Yes	
Whether shareholder approval obtained for material RPT		NA	
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee		Yes	
VI. Affirmations			
<p>1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</p> <p>2. The composition of the following committees is in terms of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015</p> <p style="margin-left: 20px;">a. Audit Committee</p> <p style="margin-left: 20px;">b. Nomination & Remuneration committee</p> <p style="margin-left: 20px;">c. Stakeholders relationship committee</p> <p>3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.</p> <p>4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.</p> <p>5. This report will be placed before Board of Directors at the ensuing Board meeting.</p>			



Name & Designation : **Gaurang C. Shah**
Company Secretary / Compliance Officer / Managing Director / CEO : **Company Secretary & Compliance Officer**

For **AJANTA PHARMA LIMITED**


GAURANG SHAH
AVP - Legal & Company Secretary

